LifeArc, an independent medical research charity, announces the appointment of Clare Terlouw as its new Head of LifeArc Ventures, effective immediately.
In this role, Clare will be responsible for developing and implementing a strategy for LifeArc’s investments across the life science sector, enhancing our commitment to funding the translation of promising life sciences research. LifeArc’s strategic investments in innovation are a key component of its charitable model, supporting both its ability to create impact for the benefit of patients and aims to contribute to its long-term sustainability.
LifeArc CEO Dr Melanie Lee said: “LifeArc plays a vital role in advancing medical research by providing the funds, advice and scientific expertise to translate early stage innovation. Clare joins LifeArc at an exciting time as we set out our plans to maximise the benefit we create for patients. Her financing and sector knowledge will help us optimise the return and impact of our investments”.
Clare was most recently at Syncona Investment Management Ltd, a FTSE250 healthcare investment trust, where she was Head of Corporate Development. She is a highly experienced and respected life sciences corporate finance and investment specialist, with significant expertise in growth funding for innovative life sciences companies in the private and public markets. Clare is also a board member of the BioIndustry Association and a non-executive director of Stevenage Bioscience Catalyst.
Janet Morgan or Surinder Maan
Mobile: 07889 591935 or 07970293826
Copyright © 2023 Stevenage Bioscience Catalyst